Indications
Vistide is indicated for the treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome (AIDS) and without renal dysfunction. Vistide should be used only when other agents are considered unsuitable.
Composition
- Active substance
- cidofovir
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Vistide
- Active substance
- cidofovir
- ATC code
- J05AB12
- Therapeutic area
- Cytomegalovirus Retinitis
- Marketing authorisation holder
- Gilead Sciences International Limited
- Status
- Withdrawn